At 7.89 PPS above Goldman PT raise today to 7.50
Low float walk-up.
Added to short- company can't cut its way to growth. Biz model doesn't work.
ER was lipstick on a pig.
Yup, she is a congenital liar.
Please find us a suitable women for President to support.
(reprint from another MB) " ..Your reply fails to acknowledge my just previous point that a Buyer now may get exactly what they want, uncrowded by competing bids and the prompt, all cash requirement typical of BK court. Further, your reply assumes BK which is not known at this time. "Going Concern" notices go out frequently without coming to fruition.
Good luck with your future investments.
Folks, this is a wild play, certainly not for anyone other than speculators who have been around the block a few times. No one should have grocery money in this- word. But for those in, be aware of sweeping declarations of what's going to happen, as if fact. None of us know except I noted in the low 2's that the risk reward ratio was enticing for a lotto size bet.
BTU Got a little ahead of itself Tuesday close so a breather yesterday.
Today, back on its bicycle to close up (2.56)
Six of last seven days have been advances
Any news of BTU doing a deal with Bowie or other and it's "to the moon, Alice!"
Prudent shorts covering some to lock in sure profits, pass on possible lunar landing.
Bloomberg Article part 3.
Valeant also said, on the Oct. 26 call, that sales hadn’t been artificially inflated because it consolidates Philidor’s results on its own books and doesn’t record those sales until prescriptions are shipped to patients.
It said it didn’t have to declare its interest in Philidor because the specialty pharmacy network has accounted for about 6 percent of Valeant revenue so far this year. That is below the 10 percent sales threshold that would make the arrangement material under Generally Accepted Accounting Principles, the company said in its presentation.
Valeant declined to provide additional comment. It has called R&O’s payment-dispute lawsuit “without merit” and said it will file a counterclaim.
Philidor referred requests for comment to public-relations firm Hill & Knowlton, which declined to comment, citing pending lawsuits. Lawyers for Isolani didn’t respond to requests for comment.
Isolani alleged in its California suit that Reitz and his pharmacy were withholding drug reimbursements that weren’t theirs, and that Reitz had breached his contractual obligations while Isolani had upheld theirs. Philidor, which is mentioned in e-mails and documents filed as part of that suit, isn’t a party.
Reitz’s lawyer, Gary Jay Kaufman, declined to comment via e-mail.
The Tiny Pharmacy at the Center of Valeant's Money Mystery
October 29, 2015 — 5:00 AM EDT
After agreeing to sell his pharmacy, owner's questions mounted
Long before investors directed a barrage of scrutiny at Valeant Pharmaceuticals International Inc., one Southern California pharmacist began pulling on a thread.
Valeant disclosed last week that it had ties to a network of pharmacies filling prescriptions for its drugs across the U.S., setting off a $10 billion drop in its market value as investors struggled to reassess the company’s sales picture. Asked why it hadn’t talked sooner about the related web of pharmacies, Valeant said that it hadn’t been bound to do so.
But the company has had little option but to explain itself in the past week thanks to a growing chorus of questions -- among the first of which came from R&O Pharmacy, a smoked-glass storefront amid rows of low-slung office buildings in Camarillo, California.
Less than a year ago, 64-year-old pharmacist Russell Reitz agreed to sell his business there to a Delaware-registered company for $350,000. R&O soon became the victim of widespread fraud, Reitz’s lawyer alleged in documents filed in a billing suit against him in state court in California.
Even before the sale agreement was executed, other pharmacies began using an R&O identification number to bill for prescriptions that R&O hadn’t filled, sometimes for drugs the store...
HAWK CFO Jerry Ulrich added, "Adjusted EBITDA grew 95%, higher than adjusted operating revenue growth due to leverage in sales and marketing, and general and administrative expenses. Excluding the reduction in cash taxes payable related to our 2014 spin-off from Safeway and the realization of acquisition-related net operating losses, adjusted net income grew 107% and adjusted diluted EPS grew 89% during the third quarter. Further, excluding 2014 and 2015 acquisitions, adjusted operating revenues grew 22% and adjusted EBITDA grew 49%."
HAWK Blackhawk Announces Third Quarter 2015 Financial Results; Adjusted Operating Revenues Rise 54% Versus Third Quarter 2014; Adjusted Net Income Increases 59%
BY GlobeNewswire — 5:00 PM ET 10/13/2015
PLEASANTON, Calif., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Blackhawk Network Holdings, Inc. (HAWK) today announced financial results for the third quarter ended September 12, 2015.
$ in millions except per share amounts Q3'15 Q3'14 % Change
Adjusted Operating Revenues $ 193.4 $ 125.4 54%
Adjusted EBITDA $ 28.6 $ 14.7 95%
Adjusted Net Income $ 19.8 $ 12.4 59%
Adjusted EPS (Diluted) $ 0.35 $ 0.23 52%
Operating Revenues (GAAP) $ 352.7 $ 269.0 31%
Ok, shortexpert, I'm willing to say there is more to this than I originally suspected.
Your posts have been informative.
I did. After being down thousands, now up $454. Went with it- got in the zone, didn't attempt to impose what I think it should be, or over think at all.
In Carolinas now, meandering north. Lovely temps following muggy My-ami.
To those who lost shorting prematurely- just try it to recoup by trading the snot out of it. These guys will probably run it to 10 break.
Doesn't make sense but it is a controlled stock for now..
Blah, blah, blah- no unattributed, factually inaccurate, obtuse posts can obscure from the knowing that PCAB is a pig in lipstick and high heels.
You're banking but will still be a #$%$ when you look in the mirror tomorrow.
ILMN is the runaway leader in sequencing. PACB is a niche player, to date selling mostly to research institutions, a narrow market.
PACB sells only about a dozen machines a year.
PACB latest iteration still is MUCH more expensive than ILMN.
PACB will have to dilute with more shares when the last small payment from Roche comes in this quarter
PACB is a highly manipulated stock, so much so Jim Cramer warned in the past not to chase it.